Privigen
Biological
CSL Behring
Total Payments
$2.6M
Transactions
2,302
Doctors
893
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $472,445 | 140 | 79 |
| 2023 | $96,313 | 206 | 120 |
| 2022 | $141,999 | 252 | 108 |
| 2021 | $493,220 | 433 | 201 |
| 2020 | $756,734 | 179 | 58 |
| 2019 | $626,795 | 366 | 69 |
| 2018 | $8,874 | 504 | 304 |
| 2017 | $12,613 | 222 | 148 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.2M | 420 | 82.7% |
| Consulting Fee | $173,172 | 44 | 6.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $112,191 | 39 | 4.3% |
| Honoraria | $78,755 | 24 | 3.0% |
| Food and Beverage | $40,476 | 1,416 | 1.6% |
| Travel and Lodging | $34,296 | 105 | 1.3% |
| Royalty or License | $10,015 | 1 | 0.4% |
| Education | $3,045 | 253 | 0.1% |
Payments by Type
Research
$2.2M
420 transactions
General
$451,950
1,882 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP | CSL Behring | $1.3M | 3 |
| A Randomized, Multicenter, Double-Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of IgPro10 (Intravenous Immunoglobulin, Privigen) for the Treatment of Adults With Systemic Sclerosis | CSL Behring | $427,388 | 0 |
| A randomized, openlabel, prospective, multicenter study designed to investigate 2 dose regimens in pediatric subjects 2 to 17 years of age with confirmed or possible CIDP, either previously exposed to IVIG treatment or unexposed to IVIG treatment | CSL Behring | $181,773 | 0 |
| Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP | CSL Behring | $142,440 | 0 |
| Scleroderma Study | CSL Behring | $108,433 | 0 |
| IVIg to Treat BK Viremia in Kidney Transplant Recipients | CSL Behring | $38,225 | 0 |
| IgPro103006 - 5 Translations in English, German, French, Italian, & Polish | CSL Behring | $3,000 | 1 |
Top Doctors Receiving Payments for Privigen
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Grand Blanc, MI | $2.2M | 599 |
| , M.D | Internal Medicine | Ann Arbor, MI | $95,020 | 37 |
| , M.D | Medical Oncology | Baltimore, MD | $17,928 | 5 |
| , M.D | Neurology | Minneapolis, MN | $16,328 | 3 |
| , MD | Allergy & Immunology | Rochester, NY | $15,814 | 6 |
| Virginia Steen | Allergy & Immunology | Washington, DC | $11,367 | 19 |
| , MD | Pediatric Allergy/Immunology | Cleveland, OH | $10,675 | 1 |
| , M.D | Student in an Organized Health Care Education/Training Program | Birmingham, AL | $10,654 | 4 |
| , M.D | Hematology & Oncology | New York, NY | $10,088 | 4 |
| , MD | Pediatrics | New Orleans, LA | $9,844 | 7 |
| , M.D | Neurology | Los Angeles, CA | $9,372 | 2 |
| , MD | Nephrology | Philadelphia, PA | $8,225 | 5 |
| , M.D | Internal Medicine | Baltimore, MD | $8,224 | 20 |
| , MD | Neurology | Phoenix, AZ | $7,890 | 1 |
| Khema Sharma | Neurology | Miami, FL | $7,501 | 2 |
| , MD | Neurology | Tampa, FL | $6,806 | 3 |
| , M.D | Neuromuscular Medicine | Kansas City, KS | $6,481 | 2 |
| , MD | Medical Oncology | Gainesville, FL | $6,200 | 2 |
| , MD | Neurology | Prescott, AZ | $6,002 | 1 |
| , MD | Neurology | Mobile, AL | $6,002 | 1 |
| , MD, MPH | Rheumatology | Radnor, PA | $5,926 | 3 |
| , MD | Allergy & Immunology | King Of Prussia, PA | $5,859 | 4 |
| , MD | Pediatric Allergy/Immunology | Sacramento, CA | $5,670 | 2 |
| , M.D | Allergy & Immunology | North Palm Beach, FL | $5,335 | 3 |
| , MD | Pediatrics | Houston, TX | $4,690 | 1 |
Ad
Manufacturing Companies
- CSL Behring $2.6M
Product Information
- Type Biological
- Total Payments $2.6M
- Total Doctors 893
- Transactions 2,302
About Privigen
Privigen is a biological associated with $2.6M in payments to 893 healthcare providers, recorded across 2,302 transactions in the CMS Open Payments database. The primary manufacturer is CSL Behring.
Payment data is available from 2017 to 2024. In 2024, $472,445 was paid across 140 transactions to 79 doctors.
The most common payment nature for Privigen is "Unspecified" ($2.2M, 82.7% of total).
Privigen is associated with 7 research studies, including "Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP" ($1.3M).